Evidence map›Paper›PMID 41279289›Full record

ArticlebioRxiv : the preprint server for biology2025

Structural and dynamic studies uncover a distinct allosteric modulatory site at the μ-opioid receptor.

Haonan Zhang, Kirill Konovalov, Alexandra K Parpounas, Davide Provasi, Shifan Yang, Alejandro Abraham, Audrey L Warren, Gregory Zilberg, Suri Wang, Marta Filizola and 1 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Haonan ZhangDepartment of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York 10029.
Kirill KonovalovDepartment of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York 10029.
Alexandra K ParpounasDepartment of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York 10029.
Davide ProvasiDepartment of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York 10029.
Shifan YangDepartment of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York 10029.
Alejandro AbrahamDepartment of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York 10029.
Audrey L WarrenDepartment of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York 10029.
Gregory ZilbergDepartment of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York 10029.
Suri WangDepartment of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York 10029.
Marta FilizolaDepartment of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York 10029.
Daniel WackerDepartment of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York 10029.

Funding

NCCAT: National Center for CryoEM Access and Training- Supplement for Windows 10 and FFIU24GM129539 · NIGMS · NEW YORK STRUCTURAL BIOLOGY CENTER · PI DE MARCO, ALEX, KIEFT, JEFFREY S · 2018 to 2023
$53.9M
Conduits: Mount Sinai Health System Translational Science HubUL1TR004419 · NCATS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Rosalind J Wright · 2022 to 2026
$46.4M
TRD #3: An automated and streamlined pipeline for in-situ molecular microscopyP41GM103310 · NIGMS · SCRIPPS RESEARCH INSTITUTE, THE · PI KIEFT, JEFFREY S · 2012 to 2021
$14.7M
Teaching biomedical and pharmacological trainees to produce FAIR data for AI & ML applicationsT32GM062754 · NIGMS · MOUNT SINAI SCHOOL OF MEDICINE OF NYU · PI SCHLESSINGER, AVNER · 2001 to 2023
$6.2M
Training Program in Substance Use DisordersT32DA053558 · NIDA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Paul J. Kenny · 2021 to 2026
$2.6M
Enhancement of the endogenous opioid system by ketamineR01DA058681 · NIDA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Lakshmi A Devi, LLOYD D FRICKER · 2023 to 2026
$2.3M
COVID and Translational Science supercomputer (CATS)S10OD030463 · OD · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KOVATCH, PATRICIA · 2021 to 2021
$2.0M
Big Omics Data Engine 2 SupercomputerS10OD026880 · OD · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KOVATCH, PATRICIA · 2019 to 2019
$2.0M
Leveraging Integrative Modeling and AI-Based Tools to Develop Safer OpioidsR01DA063209 · NIDA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Marta Filizola · 2025 to 2026
$1.5M
Acquisition of Detector for JEOL 3200 FSC Electron MicroscopeS10OD019994 · OD · NEW YORK STRUCTURAL BIOLOGY CENTER · PI CARRAGHER, BRIDGET OLIVIA · 2015 to 2015
$600k
Structural studies of psychedelic activity at the serotonin receptor 5-HT1AF31MH132317 · NIMH · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI WARREN, AUDREY LOUISE · 2022 to 2023
$85k
NCATS NIH HHS UL1 TR004419NIDA NIH HHS R01 DA058681NIDA NIH HHS R01 DA063209NIDA NIH HHS T32 DA053558NIGMS NIH HHS P41 GM103310NIGMS NIH HHS T32 GM062754NIGMS NIH HHS U24 GM129539NIH HHS S10 OD019994NIH HHS S10 OD026880NIH HHS S10 OD030463NIMH NIH HHS F31 MH132317
6 · The paper itself

Abstract

Positive allosteric modulators (PAMs) of the μ opioid receptor (MOR) offer a promising path toward safer opioid therapeutics, yet their mechanisms of action remain poorly understood. Here, we uncover the structural and mechanistic basis of BMS-986187, a chemically distinct MOR PAM with

Identifiers

PMID41279289
PMCPMC12632744

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.